Clinical Value of Single-Projection Angiography-Derived FFR in Noninfarct-Related Artery

Clinical Value of Single-Projection Angiography-Derived FFR in Noninfarct-Related Artery

Summary

The study evaluated the diagnostic accuracy of the Murray law-based quantitative flow ratio (μFR) and the safety of deferring noninfarct-related artery (non-IRA) lesions with μFR >0.80 in acute myocardial infarction (AMI) settings. The results showed that deferred non-IRA with μFR >0.80 had a lower risk of vessel-oriented composite outcome than revascularized non-IRA, making it a promising approach in patients with multivessel AMI.

Key Findings

μFR demonstrated acceptable diagnostic accuracy comparable to that of QFR to predict FFR ≤0.80, with the added benefit of shorter total analysis time. Deferred non-IRA with μFR >0.80 showed a significantly lower risk of vessel-oriented composite outcome than revascularized non-IRA, suggesting its potential as a safe strategy in the context of AMI.

Practical Solutions and Value

The use of μFR in evaluating non-IRA lesions in the setting of AMI offers a practical and time-efficient alternative with comparable diagnostic accuracy to QFR and FFR. This approach could potentially lead to improved patient outcomes and streamlined clinical workflows, offering valuable insights for clinicians managing patients with multivessel AMI.

ClinicalTrials.gov | PMID:38771911 | DOI:10.1161/CIRCINTERVENTIONS.123.013844